newsfilter
← Latest News
PR Newswire·

Anixa Biosciences' Ovarian Cancer CAR-T Therapy Inventor to Deliver Keynote at Ovarian Cancer Midwest Focus Conference

  • Anixa Biosciences announced Dr. Jose Conejo-Garcia will deliver a keynote presentation on ovarian cancer immunotherapy at the 2026 Ovarian Cancer Midwest Focus Conference.
  • The conference takes place November 2–3, 2026, in Rochester, Minnesota, hosted by Mayo Clinic & University of Minnesota.
  • Dr. Conejo-Garcia, inventor of Anixa's lira-cel CAR-T therapy, presents titled "Closing in: Cracking Ovarian Cancer's Resistance to Immunotherapy" on Tuesday, November 3, 2026, at 9:00 AM CT.
  • Anixa's investigational therapy lira-cel (liraltagene autoleucel) utilizes chimeric endocrine receptor-T cell technology targeting the follicle-stimulating hormone receptor.
  • Lira-cel is currently in a Phase 1 clinical trial with Moffitt Cancer Center to assess safety, tolerability, & preliminary efficacy.
  • No dose-limiting toxicities have been observed in the trial, with four patients surviving over one year & one patient surviving beyond two years.
  • The first patient treated at the highest dose to date exhibited stable disease 90 days post-treatment.
  • Anixa's vaccine portfolio includes breast & ovarian cancer vaccines developed with Cleveland Clinic, targeting "retired" proteins expressed in cancer.
  • Anixa operates under a business model partnering with research institutions like Moffitt & Cleveland Clinic across all development stages.